Cytori Therapeutics (CYTX)

We continue to be very positive on Cytori Therapeutics (CYTX - Analyst Report) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years.

Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results.

Today's price represents a very attractive entry point in our view. We are maintaining our Outperform rating and $8 target.